当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Why is survival after pembrolizumab affected by previous radiotherapy? – Authors' reply
The Lancet Oncology ( IF 51.1 ) Pub Date : 2017-09-01 , DOI: 10.1016/s1470-2045(17)30588-0
Percy Lee , Narek Shaverdian

We thank Farkhad Manapov and colleagues for their thoughtful commentary. Major limitations of our study include the absence of detailed information regarding the type, schedule, and dose of the delivered radiotherapy.1 Manapov and colleagues suggested that ablative radiotherapy might be a more potent stimulus for the immune system, and that definitive radiotherapy would correspond more to ablative rather than palliative radiotherapy. This might indeed be true; however, most patients in this study (64%) received radiotherapy with a palliative intent.

中文翻译:

为什么在派姆单抗治疗后的生存受到先前放疗的影响?–作者的答复

我们感谢Farkhad Manapov及其同事的周到评论。我们研究的主要局限性在于缺乏有关所放疗的类型,时间表和剂量的详细信息。1 Manapov及其同事建议,消融放疗可能是对免疫系统更有效的刺激,并且确定性放疗将更适合于消融而不是姑息放疗。这可能确实是正确的。但是,该研究中的大多数患者(64%)接受了姑息性放疗。
更新日期:2017-09-04
down
wechat
bug